Drugs / CYCLO(PROLYLGLYCYL)
CYCLO(PROLYLGLYCYL)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04480333 | Sep → Dec 2020 | COVID-19, neurodegenerative disease, neuronitis, pneumonia +1 | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03538522 | Sep 2018 → Sep 2019 | Alzheimer disease, Lewy body dementia, cognitive impairment with or without cerebellar ataxia, vascular dementia | Biomed Industries, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04540185 | Nov 2020 → Nov 2022 | COVID-19, severe acute respiratory syndrome | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04452565 Comparator | Jun 2022 → Dec 2023 | severe acute respiratory syndrome | Biomed Industries, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2024-08-26 | Biomed Industries, Inc. | Results Alzheimer's Disease and Obesity: Biomed Industries, Inc. Unveils Groundbreaking Link and New Treatment Approach biomedind.com ↗
In a Phase 2 randomized double-blind placebo controlled clinical trial, NA-831, administered orally, showed a proof of safety and efficacy for the treatment of Alzheimer’s Disease. |
| 2024-03-05 | Biomed Industries, Inc. | Results Biomed Industries Inc. Presented Groundbreaking Research at the AD/PD™ 2024 International Conference biomedind.com ↗
Both the safety and efficacy of NA-831 in our Phase 2 clinical trial has shown results that far exceed the recently FDA approved drugs for AD. |
| 2023-09-18 | Biomed Industries, Inc. | Results Biomed Industries Presented Alzheimer’s and Major Depressive Disorder Research at the Neurology World Conference biomedind.com ↗
The presentation focused on the results of the Company’s Phase 2A trial of NA-831 for AD and its Phase 1B trial for MDD, both of which showed positive patient outcomes with few, and minor, adverse events. |
| 2023-06-17 | Biomed Industries, Inc. | Results Biomed Industries, Inc. presented the Neurogenesis Hypothesis, and Phase 2A Clinical Trials Results of NA-831 at the International Conference on Neurology and Neurological Disorders, June 16-17, 2023 in Rome, ITALY biomedind.com ↗
Biomed Industries, Inc. (Biomed) introduced the Neurogenesis Hypothesis for Alzheimer's Disease and presented results of its Phase 2A clinical trial of NA-831 for the treatment of Alzheimer’s Disease (AD) at the International Conference on Neurology and Neurological Disorders, on June 16-17, 2023 in Rome, Italy ("Neurology 2023"). |
| 2023-06-16 | Biomed Industries, Inc. | Results Biomed Industries, Inc. announces results of Phase 1B pilot study for treatment of Major Depressive Disorder biomedind.com ↗
Biomed Industries, Inc. (Biomed) announced results today from its Phase 1B clinical trial of NA-831 for the treatment of Major Depressive Disorder (MDD). |
| 2023-04-01 | Biomed Industries, Inc. | Results Biomed Industries Introduced the Neurogenesis Hypothesis, and Presented Results of its Phase 2A Clinical Trials of NA-831 at the AD/PD International Conference 2023 in Sweden biomedind.com ↗
The Company also presented the Phase 2A clinical data of its new drug, NA-831, which can be taken orally for the treatment of Alzheimer’s Disease. |
| 2022-07-31 | Biomed Industries, Inc. | Results Biomed Industries, Inc.™ Inc. presented clinical results on NA-831™ at the Clinical Trials on Alzheimer's Disease (CTAD) International Conference, November 31 to Devember 2, 2022, San Francisco, California. biomedind.com ↗ |
| 2022-07-31 | Biomed Industries, Inc. | Results Biomed Industries, Inc.™ Inc. presented three scientific papers on NA-831™ at the Alzheimer's Association International Conference- July 31- August 4, 2022 in San Diego, California. biomedind.com ↗
At the AAIC 2022, Lloyd Tran, the Chairman and CSO of Biomed presented the Neurogenesis Hypothesis for Alzheimer’s (NHA) and the results of the clinical trial Phase 2A of NA-831 that supports the hypothesis. |
All press releases naming this drug 9 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYCLO(PROLYLGLYCYL) | ChEMBL registry synonym — accepted as the source's own label CHEMBL360216 ↗ |
| Known as | Cyclic glycine-proline | ChEMBL registry synonym — accepted as the source's own label CHEMBL360216 ↗ |
| Known as | NA-81 | “NA-81 is a neuroprotective drug” NCT04540185 ↗ |
| Known as | NA-831 | “Oral administration of 10 mg capsule of NA-831 QD for 24 weeks” NCT03538522 ↗ |
| Known as | Traneurocin | “NA-831 is also known as Traneurocin is a neuroprotective drug that is in clinical study for the treatment of Alzheimer's Disease.” NCT04452565 ↗ |
| Modality | Small molecule | “NA-831 is an endogenous small molecule” NCT03538522 ↗ |
| Route | Oral | “Oral administration of 10 mg capsule of NA-831 QD for 24 weeks” NCT03538522 ↗ |